As of November 6, 2026, Corvus Pharmaceuticals, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 23, 2026 to July 22, 2026, naming 1 appointment. The latest filing names Andrew C. Chan, appointed (Form 8-K, July 22, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Corvus Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Corvus Pharmaceuticals, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-23 to 2026-07-22. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Corvus Pharmaceuticals, Inc. files it.
Also on the record for Corvus Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.3% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7.5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Sirenia Capital Management LP | 7.5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | — | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.4% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Richard A. Miller | 7.8% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13D/A, by Adams Street Partners, LLC | 3.9% of the class | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G, by The Vanguard Group | 5.18% of the class | 5%+ stakes | Source |
| January 27, 2026 | Stake report, Schedule 13D/A, by ORBIMED ADVISORS LLC | 10.3% of the class | 5%+ stakes | Source |
| October 17, 2025 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.4% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by SAMLYN CAPITAL, LLC | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Corvus Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Corvus Pharmaceuticals, Inc. and the records around it.
Corvus Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- SAMLYN CAPITAL, LLC also filed stake reports on 2 other companies: PureCycle Technologies, Inc. (May 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Watch Corvus Pharmaceuticals, Inc.
Get an email when Corvus Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Corvus Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Corvus Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Corvus Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-22 | Reported | not named in the filing | 8-K, 2026-07-22 | ||
| 2026-04-23 | In | 2026-04-23 | 8-K, 2026-04-23 |
New leaders reset buying decisions — get the Full Report on Corvus Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Corvus Pharmaceuticals, Inc., with the record behind each one.
Find candidates like senior executive at Corvus Pharmaceuticals, Inc.Every change, in the filing's words
Reported
On July 21, 2026, Ian T. Clark delivered notice of his intention to resign from the board of directors (the "Board") of Corvus Pharmaceuticals, Inc. (the "Company"), effective as of July 22, 2026.
- The Company thanks Mr. Clark for his significant contributions to the Company during over nine years of Board service.
Appointed: Andrew C. Chan, effective 2026-04-23
On April 22, 2026, the Board of Directors (the "Board") of Corvus Pharmaceuticals, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the "Nominating Committee"), appointed Andrew C. Chan, M.D., Ph.D., to the Board, effective April 23, 2026.
- Dr. Chan was appointed as a Class II director with a term expiring at the 2027 annual meeting of stockholders and until his successor is elected and qualified, or until his earlier death, resignation or removal.
- Dr. Chan was also appointed to the Nominating Committee, effective April 23, 2026.
- Pursuant to the Company's non-employee director compensation program, as a non-employee director, Dr. Chan will receive (i) a $35,000 annual retainer for his service on the Board, earned on a quarterly basis and prorated for the remainder of the current calendar quarter and (ii) an automatic initial grant of a stock option to purchase 30,000 shares of Common Stock under the Company's 2016 Equity Incentive Award Plan.
- Dr. Chan will receive additional annual cash compensation of $4,000 for his service as a member of the Nominating Committee, earned on a quarterly basis and prorated for the remainder of the current calendar quarter.
- Dr. Chan will also be eligible for subsequent equity awards in accordance with the Company's non-employee director compensation program.
- On April 22, 2026, Scott Morrison delivered notice of his intention to resign from the Board effective as of April 23, 2026.
- The Company thanks Mr. Morrison for his significant contributions to the Company during over a decade of Board service and for his leadership as Chairperson of the Audit Committee of the Board.
Tools for this story
Each opens in a new tab, filled in for Corvus Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.